Evidence Hub

A rapid in vivo pipeline to identify small molecule inhibitors of amyloid aggregation

Muntasir Kamal, Jessica J. Knox, Robert I. Horne, Om Shanker Tiwari, Andrew R. Burns, Duhyun Han, Davide Levy, Dana Laor Bar‐Yosef et al.

Nature Communications, 2024

7 citations

Abstract

Amyloids are associated with over 50 human diseases and have inspired significant effort to identify small molecule remedies. Here, we present an in vivo platform that efficiently yields small molecule inhibitors of amyloid formation. We previously identified small molecules that kill the nematode C. elegans by forming membrane-piercing crystals in the pharynx cuticle, which is rich in amyloid-like material. We show here that many of these molecules are known amyloid-binders whose crystal-formation in the pharynx can be blocked by amyloid-binding dyes. We asked whether this phenomenon could be exploited to identify molecules that interfere with the ability of amyloids to seed higher-order structures. We therefore screened 2560 compounds and found 85 crystal suppressors, 47% of which inhibit amyloid formation. This hit rate far exceeds other screening methodologies. Hence, in vivo screens for suppressors of crystal formation in C. elegans can efficiently reveal small molecules with amyloid-inhibiting potential. In this work, Kamal, Knox et al develop a high-throughput system to identify small molecules that disrupt amyloid formation by pre-selecting compounds that suppress molecular interactions within the cuticle of the C. elegans pharynx.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free